Sign In
Buy XERS
$5.89
-0.110 (-1.83%)
At Close: Jun 03, 2026
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
10:16am, Tuesday, 12'th Aug 2025
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript
07:38pm, Thursday, 07'th Aug 2025
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Comm
Xeris (XERS) Q2 Revenue Jumps 49%
11:55am, Thursday, 07'th Aug 2025
Xeris (XERS) Q2 Revenue Jumps 49%
Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Thursday, 07'th Aug 2025
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street e
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
09:36am, Thursday, 07'th Aug 2025
Xeris Biopharma (XERS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.1 per share a year ago.
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
07:00am, Thursday, 07'th Aug 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
07:30am, Thursday, 31'st Jul 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing
10:17am, Wednesday, 18'th Jun 2025
Compared to other biotech companies, Xeris Biopharma Holdings Inc. is a company that has successfully launched products that are already generating revenue. As the company's revenue is expected to gro
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
07:30am, Tuesday, 03'rd Jun 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Xeris Announces Details for Analyst & Investor Day
07:30am, Tuesday, 20'th May 2025
CHICAGO--(BUSINESS WIRE)--Xeris Announces Details for Analyst & Investor Day.
Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript
02:15pm, Thursday, 08'th May 2025
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pie
Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates
09:20am, Thursday, 08'th May 2025
Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.14 per share a year ago.
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
07:00am, Thursday, 08'th May 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings
11:51am, Wednesday, 07'th May 2025
Xeris Biopharma Holdings, Inc. has shown consistent double-digit growth and is expected to continue this trend, with Q1 earnings projected to drive the share price higher. Key metrics to watch include
Xeris Announces Changes to Its Board of Directors
08:00am, Friday, 28'th Mar 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative p
